Russian researchers have developed a new method that can improve diagnosis of colorectal cancer or what is commonly known as bowel cancer.
Colorectal cancer is the third most common type of cancer and it develops with minimal clinical symptoms in the early stages.
Despite doctors' efforts, the five-year survival rate does not exceed 36 percent. Treatment is only effective, and patients only have a good chance of recovery, if the cancer is detected early.
Diagnostic methods that are currently in use are not sufficient. Analyses carried out in vitro have low specificity and invasive studies such as colonoscopy are not only traumatic, but they are also not always suitable for an early diagnosis, as they do not give a complete picture of the development and distribution of colorectal cancer.
The new method proposed by the scientists is based on the simultaneous detection of various substances in patients' blood.
These substances are autoantibodies against tumour-associated biological molecules called glycans, which can be found in serum at the early stages of cancer.
Tumour cells have special glycans enabling scientists to differentiate them from healthy cells, and this is the key aspect of the new study.
"The method developed at EIMB RAS (Engelhardt Institute of Molecular Biology in Moscow) has great potential to be used in diagnosing gastrointestinal diseases. We hope that testing systems based on the method will soon appear in clinical laboratories in Russia," said one of the authors Zhanna Zubtsova, assistant professor at Moscow Institute of Physics and Technology (MIPT).
The results of the study were published in the journal Cancer Medicine.
The researchers said that the method surpasses all other existing methods. The model of the test-system based on diagnostic signatures was able to diagnose colorectal cancer in 95 percent of cases, compared to 79 percent detected by traditional methods.
The sensitivity of detection (in patients with advanced bowel cancer) was 87 percent versus 21 percent.
This increase is clearly a significant achievement, the researchers said.
--IANS
gb/vm
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
